Search

Your search keyword '"Xu-Monette, Zijun Y"' showing total 499 results
Start Over Author "Xu-Monette, Zijun Y"
499 results on '"Xu-Monette, Zijun Y"'

1. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma

Author

Sircar, Anuvrat, Singh, Satishkumar, Xu-Monette, Zijun Y., Coyle, Krysta Mila, Hilton, Laura K., Chavdoula, Evangelia, Ranganathan, Parvathi, Jain, Neeraj, Hanel, Walter, Tsichlis, Philip, Alinari, Lapo, Peterson, Blake R., Tao, Jianguo, Muthusamy, Natarajan, Baiocchi, Robert, Epperla, Narendranath, Young, Ken H., Morin, Ryan, and Sehgal, Lalit

Published
2023
Full Text
View/download PDF

2. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Author

Al-Juhaishi, Taha, Wang, Yingjun, Milton, Denái R., Xu-Monette, Zijun Y., Jabbour, Elias, Daher, May, Im, Jin S., Bashir, Qaiser, Iyer, Swaminathan P., Marin, David, Olson, Amanda L., Popat, Uday, Qazilbash, Muzaffar, Rondon, Gabriela, Gulbis, Alison M., Champlin, Richard E., Young, Ken H., and Khouri, Issa F.

Published
2023
Full Text
View/download PDF

6. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Author

Xu-Monette, Zijun Y, Zhang, Hongwei, Zhu, Feng, Tzankov, Alexandar, Bhagat, Govind, Visco, Carlo, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Møller, Michael B, Parsons, Benjamin M, van Krieken, J Han, Piris, Miguel A, Winter, Jane N, Hagemeister, Fredrick B, Shahbaba, Babak, De Dios, Ivan, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher, and Young, Ken H

Subjects
Orphan Drug, Human Genome, Hematology, Cancer, Rare Diseases, Lymphoma, Biotechnology, Genetics, Generic health relevance, Good Health and Well Being, Artificial Intelligence, B-Lymphocytes, Germinal Center, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, Large B-Cell, Diffuse
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights. Genetic subtypes uncovered recently are based on distinct genetic alterations in DLBCL, which are different from the COO subtypes defined by gene expression signatures of normal B cells retained in DLBCL. We hypothesize that classifiers incorporating both genome-wide gene-expression and pathogenetic variables can improve the therapeutic significance of DLBCL classification. To develop such refined classifiers, we performed targeted RNA sequencing (RNA-Seq) with a commercially available next-generation sequencing (NGS) platform in a large cohort of 418 DLBCLs. Genetic and transcriptional data obtained by RNA-Seq in a single run were explored by state-of-the-art artificial intelligence (AI) to develop a NGS-COO classifier for COO assignment and NGS survival models for clinical outcome prediction. The NGS-COO model built through applying AI in the training set was robust, showing high concordance with COO classification by either Affymetrix GeneChip microarray or the NanoString Lymph2Cx assay in 2 validation sets. Although the NGS-COO model was not trained for clinical outcome, the activated B-cell-like compared with the germinal-center B-cell-like subtype had significantly poorer survival. The NGS survival models stratified 30% high-risk patients in the validation set with poor survival as in the training set. These results demonstrate that targeted RNA-Seq coupled with AI deep learning techniques provides reproducible, efficient, and affordable assays for clinical application. The clinical grade assays and NGS models integrating both genetic and transcriptional factors developed in this study may eventually support precision medicine in DLBCL.

Published
2020

7. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.

Author

Xu-Monette, Zijun Y., Luo, Cancan, Yu, Li, Li, Yong, Bhagat, Govind, Tzankov, Alexandar, Visco, Carlo, Fan, Xiangshan, Dybkaer, Karen, Sakhdari, Ali, Wang, Nicholas T., Yuan, Alyssa F., Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Perry, Anamarija M., Song, Wenting, O'Malley, Dennis, and Au, Qingyan

Subjects
*DIFFUSE large B-cell lymphomas, *GENE expression, *GENE expression profiling, *T cells, *GENE silencing, *DNA mismatch repair
Abstract

Deficient (d) DNA mismatch repair (MMR) is a biomarker predictive of better response to PD-1 blockade immunotherapy in solid tumors. dMMR can be caused by mutations in MMR genes or by protein inactivation, which can be detected by sequencing and immunohistochemistry, respectively. To investigate the role of dMMR in diffuse large B-cell lymphoma (DLBCL), MMR gene mutations and expression of MSH6, MSH2, MLH1, and PMS2 proteins were evaluated by targeted next-generation sequencing and immunohistochemistry in a large cohort of DLBCL patients treated with standard chemoimmunotherapy, and correlated with the tumor immune microenvironment characteristics quantified by fluorescent multiplex immunohistochemistry and gene-expression profiling. The results showed that genetic dMMR was infrequent in DLBCL and was significantly associated with increased cancer gene mutations and favorable immune microenvironment, but not prognostic impact. Phenotypic dMMR was also infrequent, and MMR proteins were commonly expressed in DLBCL. However, intratumor heterogeneity existed, and increased DLBCL cells with phenotypic dMMR correlated with significantly increased T cells and PD-1+ T cells, higher average nearest neighbor distance between T cells and PAX5+ cells, upregulated immune gene signatures, LE4 and LE7 ecotypes and their underlying Ecotyper-defined cell states, suggesting the possibility that increased T cells targeted only tumor cell subsets with dMMR. Only in patients with MYC¯ DLBCL, high MSH6/PMS2 expression showed significant adverse prognostic effects. This study shows the immunologic and prognostic effects of genetic/phenotypic dMMR in DLBCL, and raises a question on whether DLBCL-infiltrating PD-1+ T cells target only tumor subclones, relevant for the efficacy of PD-1 blockade immunotherapy in DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma

Author

Elfrink, Suraya, ter Beest, Martin, Janssen, Luuk, Baltissen, Marijke P., Jansen, Pascal W.T.C., Kenyon, Angelique N., Steen, Raymond M., de Windt, Daynelys, Hagemann, Philipp M., Hess, Corine, van Spronsen, Dick-Johan, Hoevenaars, Brigiet, van der Spek, Ellen, Xu-Monette, Zijun Y., Young, Ken H., Kaffa, Charlotte, Bervoets, Sander, van Heek, Jolien, Hesius, Eva, de Winde, Charlotte M., Vermeulen, Michiel, van den Brand, Michiel, Scheijen, Blanca, and van Spriel, Annemiek B.

Published
2022
Full Text
View/download PDF

9. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

Author

Tian, Xiao-Peng, Ma, Shu-Yun, Young, Ken H., Ong, Choon Kiat, Liu, Yan-Hui, Li, Zhi-Hua, Zhai, Qiong-Li, Huang, Hui-Qiang, Lin, Tong-Yu, Li, Zhi-Ming, Xia, Zhong-Jun, Zhong, Li-Ye, Rao, Hui-Lan, Li, Mei, Cai, Jun, Zhang, Yu-Chen, Zhang, Fen, Su, Ning, Li, Peng-Fei, Zhu, Feng, Xu-Monette, Zijun Y., Wong, Esther Kam Yin, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Ai, Le, Cheng, Run-Fen, Lim, Jing Quan, de Mel, Sanjay, Ng, Siok-Bian, Lim, Soon Thye, and Cai, Qing-Qing

Published
2021
Full Text
View/download PDF

12. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

Author

Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark, and Gandhi, Maher K.

Published
2020
Full Text
View/download PDF

13. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Author

Albitar, Maher, Zhang, Hong, Goy, Andre, Xu-Monette, Zijun Y., Bhagat, Govind, Visco, Carlo, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, and Young, Ken H.

Published
2022
Full Text
View/download PDF

14. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program

Author

Li, Ling, Sun, Ruifang, Miao, Yi, Tran, Thai, Adams, Lisa, Roscoe, Nathan, Xu, Bing, Manyam, Ganiraju C., Tan, Xiaohong, Zhang, Hongwei, Xiao, Min, Tzankov, Alexandar, Visco, Carlo, Dybkaer, Karen, Bhagat, Govind, Tam, Wayne, Hsi, Eric D., van Krieken, J.Han, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Piris, Miguel A., Zhang, Mingzhi, Winter, Jane N., Medeiros, L.Jeffrey, Rassidakis, George Z., Vaupel, Christine A., Li, Yong, Dakappagari, Naveen, Xu-Monette, Zijun Y., and Young, Ken H.

Published
2019
Full Text
View/download PDF

17. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma

Author

Wang, Xiaoxiao, Cao, Xin, Sun, Ruifang, Tang, Charlene, Tzankov, Alexandar, Zhang, Jun, Manyam, Ganiraju C., Xiao, Min, Miao, Yi, Jabbar, Kausar, Tan, Xiaohong, Pang, Yuyang, Visco, Carlo, Xie, Yan, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Ben M., Winter, Jane N., Piris, Miguel A., Li, Shaoying, Miranda, Roberto N., Medeiros, L. Jeffrey, Li, Yong, Xu-Monette, Zijun Y., and Young, Ken H.

Published
2018
Full Text
View/download PDF

19. Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

Author

Xu-Monette, Zijun Y., primary, Li, Yong, additional, Snyder, Thomas, additional, Yu, Tiantian, additional, Lu, Tingxun, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Qian, Wenbin, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Wang, Yingjun, additional, Go, Heounjeong, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Moller, Michael B., additional, Parsons, Benjamin M., additional, Fan, Xiangshan, additional, van Krieken, J.Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Au, Qingyan, additional, Kirsch, Ilan, additional, Zhang, Mingzhi, additional, Shaughnessy, John, additional, Xu, Bing, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

20. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

Author

Chung, Elaine Y. L., primary, Sartori, Giulio, additional, Ponzoni, Maurilio, additional, Cascione, Luciano, additional, Priebe, Valdemar, additional, Xu‐Monette, Zijun Y., additional, Fang, Xiaosheng, additional, Zhang, Mingzhi, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Rinaldi, Andrea, additional, Sgrignani, Jacopo, additional, Zucca, Emanuele, additional, Rossi, Davide, additional, Cavalli, Andrea, additional, Inghirami, Giorgio, additional, Scott, David W., additional, Young, Ken H., additional, and Bertoni, Francesco, additional

Published
2023
Full Text
View/download PDF

21. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma

Author

Wang, Jinfen, Xu-Monette, Zijun Y., Jabbar, Kausar J., Shen, Qi, Manyam, Ganiraju C., Tzankov, Alexandar, Visco, Carlo, Wang, Jing, Montes-Moreno, Santiago, Dybkær, Karen, Tam, Wayne, Bhagat, Govind, Hsi, Eric D., van Krieken, J. Han, Ponzoni, Maurilio, Ferreri, Andrés J.M., Wang, Shi, Møller, Michael B., Piris, Miguel A., Medeiros, L. Jeffrey, Li, Yong, Pham, Lan V., and Young, Ken H.

Published
2017
Full Text
View/download PDF

25. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Author

Deng, Manman, Zhang, Mingzhi, Xu-Monette, Zijun Y., Pham, Lan V., Tzankov, Alexandar, Visco, Carlo, Fang, Xiaosheng, Bhagat, Govind, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Choi, William W. L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick, Alinari, Lapo, Li, Yong, Andreeff, Michael, Xu, Bing, and Young, Ken H.

Published
2020
Full Text
View/download PDF

29. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.

Author

Tiantian Yu, Xu-Monette, Zijun Y., Lagoo, Anand, Wen Shuai, Bangchen Wang, Neff, Jadee, Carrillo, Luis F., Carlsen, Eric D., Pina-Oviedo, Sergio, and Young, Ken H.

Subjects
TUMOR-infiltrating immune cells, DIFFUSE large B-cell lymphomas, FLOW cytometry, OVERALL survival, B cells, KILLER cells
Abstract

Introduction: Our previous studies have demonstrated that tumor-infiltrating lymphocytes (TILs), including normal B cells, T cells, and natural killer (NK) cells, in diffuse large B-cell lymphoma (DLBCL) have a significantly favorable impact on the clinical outcomes of patients treated with standard chemoimmunotherapy. In this study, to gain a full overview of the tumor immune microenvironment (TIME), we assembled a flow cytometry cohort of 102 patients diagnosed with DLBCL at the Duke University Medical Center. Methods: We collected diagnostic flow cytometry data, including the proportion of T cells, abnormal B cells, normal B cells, plasma cells, NK cells, monocytes, and granulocytes in fresh biopsy tissues at clinical presentation, and analyzed the correlations with patient survival and between different cell populations. Results: We found that low T cell percentages in all viable cells and low ratios of T cells to abnormal B cells correlated with significantly poorer survival, whereas higher percentages of normal B cells among total B cells (or high ratios of normal B cells to abnormal B cells) and high percentages of NK cells among all viable cells correlated with significantly better survival in patients with DLBCL. After excluding a small number of patientswith low T cell percentages, the normal B cell percentage among all B cells, but not T cell percentage among all cells, continued to show a remarkable prognostic effect. Data showed significant positive correlations between T cells and normal B cells, and between granulocytes and monocytes. Furthermore, we constructed a prognostic model based on clinical and flow cytometry factors, which divided the DLBCL cohort into two equal groups with remarkable differences in patient survival and treatment response. Summary: TILs, including normal B cells, T cells, and NK cells, are associated with favorable clinical outcomes in DLBCL, and flow cytometry capable of quantifying the TIME may have additional clinical utility for prognostication. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Author

Xu-Monette, Zijun Y., Li, Ling, Byrd, John C., Jabbar, Kausar J., Manyam, Ganiraju C., Maria de Winde, Charlotte, van den Brand, Michiel, Tzankov, Alexandar, Visco, Carlo, Wang, Jing, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Ben M., Winter, Jane N., Wang, Michael, Hagemeister, Frederick B., Piris, Miguel A., Han van Krieken, J., Medeiros, L.Jeffrey, Li, Yong, van Spriel, Annemiek B., and Young, Ken H.

Published
2016
Full Text
View/download PDF

33. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Author

Xu-Monette, Zijun Y., Li, Jianyong, Xia, Yi, Crossley, Beryl, Bremel, Robert D., Miao, Yi, Xiao, Min, Snyder, Thomas, Manyam, Ganiraju C., Tan, Xiaohong, Zhang, Hongwei, Visco, Carlo, Tzankov, Alexandar, Dybkaer, Karen, Bhagat, Govind, Tam, Wayne, You, Hua, Hsi, Eric D., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Piris, Miguel A., Winter, Jane N., Medeiros, Jeffrey T., Xu, Bing, Li, Yong, Kirsch, Ilan, and Young, Ken H.

Published
2019
Full Text
View/download PDF

35. Data from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Author

Deng, Manman, primary, Xu-Monette, Zijun Y., primary, Pham, Lan V., primary, Wang, Xudong, primary, Tzankov, Alexandar, primary, Fang, Xiaosheng, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, You, Hua, primary, Huh, Jooryung, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, Hagemeister, Fredrick, primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Liu, Phillip, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Tables 1-5 and Supplementary Figures 1-8 from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Author

Deng, Manman, primary, Xu-Monette, Zijun Y., primary, Pham, Lan V., primary, Wang, Xudong, primary, Tzankov, Alexandar, primary, Fang, Xiaosheng, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, You, Hua, primary, Huh, Jooryung, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, Hagemeister, Fredrick, primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Liu, Phillip, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

37. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Author

Li, Yong, primary, Xu-Monette, Zijun Y., additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Bhagat, Govind, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Zhang, Shanxiang, additional, Dybkaer, Karen, additional, Pan, Zenggang, additional, Xu, Min, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Go, Heounjeong, additional, van Krieken, J. Han, additional, Winter, Jane N., additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Wang, Yingjun, additional, Zhang, Mingzhi, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

38. Supplmentary Documents including Methods, Tables, and Legends for Supplementary Figures, and Supplementary Figure S1-S5 from Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Deng, Qipan, primary, Manyam, Ganiraju C., primary, Tzankov, Alexander, primary, Li, Ling, primary, Xia, Yi, primary, Wang, Xiao-xiao, primary, Zou, Dehui, primary, Visco, Carlo, primary, Dybkær, Karen, primary, Li, Jun, primary, Zhang, Li, primary, Liang, Han, primary, Montes-Moreno, Santiago, primary, Chiu, April, primary, Orazi, Attilio, primary, Zu, Youli, primary, Bhagat, Govind, primary, Richards, Kristy L., primary, Hsi, Eric D., primary, Choi, William W.L., primary, van Krieken, J. Han, primary, Huh, Jooryung, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Parsons, Ben M., primary, Møller, Michael B., primary, Wang, Sa A., primary, Miranda, Roberto N., primary, Piris, Miguel A., primary, Winter, Jane N., primary, Medeiros, L. Jeffrey, primary, Li, Yong, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

Author

Ok, Chi Young, primary, Li, Ling, primary, Xu-Monette, Zijun Y., primary, Visco, Carlo, primary, Tzankov, Alexander, primary, Manyam, Ganiraju C., primary, Montes-Moreno, Santiago, primary, Dybaer, Karen, primary, Chiu, April, primary, Orazi, Attilio, primary, Zu, Youli, primary, Bhagat, Govind, primary, Chen, Jiayu, primary, Richards, Kristy L., primary, Hsi, Eric D., primary, Choi, William W. L., primary, van Krieken, J. Han, primary, Huh, Jooryung, primary, Ai, Weiyun, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Farnen, John P., primary, Møller, Michael B., primary, Bueso-Ramos, Carlo E., primary, Miranda, Roberto N., primary, Winter, Jane N., primary, Piris, Miguel A., primary, Medeiros, L. Jeffrey, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

Author

Ok, Chi Young, primary, Li, Ling, primary, Xu-Monette, Zijun Y., primary, Visco, Carlo, primary, Tzankov, Alexander, primary, Manyam, Ganiraju C., primary, Montes-Moreno, Santiago, primary, Dybaer, Karen, primary, Chiu, April, primary, Orazi, Attilio, primary, Zu, Youli, primary, Bhagat, Govind, primary, Chen, Jiayu, primary, Richards, Kristy L., primary, Hsi, Eric D., primary, Choi, William W. L., primary, van Krieken, J. Han, primary, Huh, Jooryung, primary, Ai, Weiyun, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Farnen, John P., primary, Møller, Michael B., primary, Bueso-Ramos, Carlo E., primary, Miranda, Roberto N., primary, Winter, Jane N., primary, Piris, Miguel A., primary, Medeiros, L. Jeffrey, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

43. Supplement Figures 1 - 5 and Tables 1 - 6 from Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Author

Ok, Chi Young, primary, Chen, Jiayu, primary, Xu-Monette, Zijun Y., primary, Tzankov, Alexandar, primary, Manyam, Ganiraju C., primary, Li, Ling, primary, Visco, Carlo, primary, Montes-Moreno, Santiago, primary, Dybkær, Karen, primary, Chiu, April, primary, Orazi, Attilio, primary, Zu, Youli, primary, Bhagat, Govind, primary, Richards, Kristy L., primary, Hsi, Eric D., primary, Choi, William W.L., primary, van Krieken, J. Han, primary, Huh, Jooryung, primary, Zhao, Xiaoying, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Bertoni, Francesco, primary, Farnen, John P., primary, Møller, Michael B., primary, Piris, Miguel A., primary, Winter, Jane N., primary, Medeiros, L. Jeffrey, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

44. Data from Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Author

Ok, Chi Young, primary, Chen, Jiayu, primary, Xu-Monette, Zijun Y., primary, Tzankov, Alexandar, primary, Manyam, Ganiraju C., primary, Li, Ling, primary, Visco, Carlo, primary, Montes-Moreno, Santiago, primary, Dybkær, Karen, primary, Chiu, April, primary, Orazi, Attilio, primary, Zu, Youli, primary, Bhagat, Govind, primary, Richards, Kristy L., primary, Hsi, Eric D., primary, Choi, William W.L., primary, van Krieken, J. Han, primary, Huh, Jooryung, primary, Zhao, Xiaoying, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Bertoni, Francesco, primary, Farnen, John P., primary, Møller, Michael B., primary, Piris, Miguel A., primary, Winter, Jane N., primary, Medeiros, L. Jeffrey, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

46. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Author

Xu-Monette, Zijun Y, Dabaja, Bouthaina S, Wang, Xiaoxiao, Tu, Meifeng, Manyam, Ganiraju C, Tzankov, Alexander, Xia, Yi, Zhang, Li, Sun, Ruifang, Visco, Carlo, Dybkaer, Karen, Yin, Lihui, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Choi, William WL, van Krieken, J Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Møller, Michael B, Parsons, Ben M, Zhao, Xiaoying, Winter, Jane N, Piris, Miguel A, McDonnell, Timothy J, Miranda, Roberto N, Li, Yong, Medeiros, L Jeffrey, and Young, Ken H

Published
2015
Full Text
View/download PDF

47. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Author

Liu, Zhiyu, Xu-Monette, Zijun Y, Cao, Xin, Manyam, Ganiraju C, Wang, Xiaoxiao, Tzankov, Alexandar, Xia, Yi, Li, Xin, Visco, Carlo, Sun, Ruifang, Zhang, Li, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Choi, William WL, van Krieken, J Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Parsons, Ben M, Møller, Michael B, Piris, Miguel A, Winter, Jane N, O'Malley, Dennis P, Medeiros, L Jeffrey, and Young, Ken H

Published
2015
Full Text
View/download PDF

48. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

Author

Ok, Chi Young, Xu-Monette, Zijun Y, Li, Ling, Manyam, Ganiraju C, Montes-Moreno, Santiago, Tzankov, Alexandar, Visco, Carlo, Dybkær, Karen, Routbort, Mark J, Zhang, Li, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Choi, William W L, van Krieken, J Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J M, Parsons, Ben M, Rao, Huilan, Møller, Michael B, Winter, Jane N, Piris, Miguel A, Wang, Sa A, Medeiros, L Jeffrey, and Young, Ken H

Published
2015
Full Text
View/download PDF

49. Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma

Author

Yu, Tiantian, Luo, Dan, Luo, Cancan, Xu-Monette, Zijun Y, and Yu, Li

Subjects
Original Article
Abstract

Lipid metabolism is associated with lymphomagenesis and functions as a new therapeutic target in patients with lymphoma. Several serum lipids and lipoproteins have prognostic value in solid tumors; however, their value in diffuse large B-cell lymphoma (DLBCL) has been poorly described. We retrospectively analyzed and compared pre-treatment serum lipid and lipoprotein levels, including triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (ApoA-I), and apolipoprotein B (ApoB) between 105 DLBCL and 105 controls (no DLBCL). The prognostic significance of serum lipid and lipoprotein levels was determined using univariate and multivariate Cox proportional hazards models. The primary outcomes, overall survival (OS) and progression-free survival (PFS), were assessed by the Kaplan-Meier method. We combined the International Prognostic Index (IPI) with ApoA-I to build a nomogram model (IPI-A) to predict the OS and PFS of DLBCL. Serum TG, LDL-C, HDL-C, ApoA-I, and ApoB levels were significantly lower in the DLBCL patients than in controls and significantly increased after chemotherapy. Multivariate analyses showed that the ApoA-I level was an independent predictor of OS and PFS. In addition, our findings indicated that the prognostic index IPI-A significantly improves risk prediction over the traditional IPI score system. ApoA-I is an independent prognostic factor associated with poor OS and PFS in DLBCL patients. Our findings suggested that IPI-A is a prognostic index accurately used for risk assessment in patients with DLBCL.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results